B Qu1, Y Ma, M Yan, H-H Wu, L Fan, D-F Liao, X-M Pan, Z Hong. 1. Department of Orthopaedics, Chengdu Military General Hospital, No. 270, Tianhui Road, Rongdu Avenue, Chengdu, Sichuan, 610083, People's Republic of China.
Abstract
UNLABELLED: To study the cost of osteoporotic fracture in China, we performed a prospective study and compared the costs of the disease in referral patients with fractures in three of the most common sites. Our results indicated that the economic burden of osteoporotic fracture to both Chinese patients and the nation is heavy. INTRODUCTION: This paper aims to study the cost of osteoporotic fracture in China and thus to provide essential information about the burden of this disease to individuals and society. METHODS: This prospective observational data collection study assessed the cost related to hip, vertebral, and wrist fracture 1 year after the fracture based on a patient sample consisting of 938 men and women. Information was collected using patient records, registry sources, and patient interviews. Both direct medical, direct non-medical, and indirect non-medical costs were considered. RESULTS: The annual total costs were highest in hip fracture patients (renminbi, RMB 27,283 or USD 4,330, with confidence interval (RMB 25715, 28851)), followed by patients with vertebral fracture (RMB 21,474 or USD 3,409, with confidence interval (RMB 20082, 22866)) and wrist fracture (RMB 8,828 or USD 1,401, with confidence interval (RMB 7829, 9827)). The direct medical care costs averaged approximately RMB 17,007 per year per patient, of which inpatient costs, drugs, and investigations accounted for the majority of the costs. Nonmedical direct costs were much less compared to direct healthcare costs and averaged approximately RMB 1,846. CONCLUSION: These results indicate that the economic burden of osteoporotic fracture to both Chinese patients and China was heavy, and the proportion of the costs in China demonstrated many similar features and some significant differences compared to other countries.
UNLABELLED: To study the cost of osteoporotic fracture in China, we performed a prospective study and compared the costs of the disease in referral patients with fractures in three of the most common sites. Our results indicated that the economic burden of osteoporotic fracture to both Chinese patients and the nation is heavy. INTRODUCTION: This paper aims to study the cost of osteoporotic fracture in China and thus to provide essential information about the burden of this disease to individuals and society. METHODS: This prospective observational data collection study assessed the cost related to hip, vertebral, and wrist fracture 1 year after the fracture based on a patient sample consisting of 938 men and women. Information was collected using patient records, registry sources, and patient interviews. Both direct medical, direct non-medical, and indirect non-medical costs were considered. RESULTS: The annual total costs were highest in hip fracturepatients (renminbi, RMB 27,283 or USD 4,330, with confidence interval (RMB 25715, 28851)), followed by patients with vertebral fracture (RMB 21,474 or USD 3,409, with confidence interval (RMB 20082, 22866)) and wrist fracture (RMB 8,828 or USD 1,401, with confidence interval (RMB 7829, 9827)). The direct medical care costs averaged approximately RMB 17,007 per year per patient, of which inpatient costs, drugs, and investigations accounted for the majority of the costs. Nonmedical direct costs were much less compared to direct healthcare costs and averaged approximately RMB 1,846. CONCLUSION: These results indicate that the economic burden of osteoporotic fracture to both Chinese patients and China was heavy, and the proportion of the costs in China demonstrated many similar features and some significant differences compared to other countries.
Authors: Crystal Pike; Howard G Birnbaum; Matt Schiller; Hari Sharma; Russel Burge; Eric T Edgell Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: Michael C Nevitt; Ling Xu; Yuqing Zhang; Li-Yung Lui; Wei Yu; Nancy E Lane; Mingwei Qin; Marc C Hochberg; Steven R Cummings; David T Felson Journal: Arthritis Rheum Date: 2002-07
Authors: Z Chen; M Maricic; A K Aragaki; C Mouton; L Arendell; A M Lopez; T Bassford; R T Chlebowski Journal: Osteoporos Int Date: 2008-09-03 Impact factor: 4.507
Authors: F Borgström; I Lekander; M Ivergård; O Ström; A Svedbom; V Alekna; M L Bianchi; P Clark; M D Curiel; H P Dimai; M Jürisson; R Kallikorm; O Lesnyak; E McCloskey; E Nassonov; K M Sanders; S Silverman; M Tamulaitiene; T Thomas; A N A Tosteson; B Jönsson; J A Kanis Journal: Osteoporos Int Date: 2013-01-10 Impact factor: 4.507
Authors: F Guillemin; L Martinez; M Calvert; C Cooper; T Ganiats; M Gitlin; R Horne; A Marciniak; J Pfeilschifter; S Shepherd; A Tosteson; S Wade; D Macarios; N Freemantle Journal: Osteoporos Int Date: 2013-06-11 Impact factor: 4.507
Authors: J Wang; D Yan; A Zhao; X Hou; X Zheng; P Chen; Y Bao; W Jia; C Hu; Z-L Zhang; W Jia Journal: Osteoporos Int Date: 2019-02-18 Impact factor: 4.507